Celldex Therapeutics, Inc.: net property, plant and equipment
Net property, plant and equipment for Celldex Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Celldex Therapeutics, Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 5,334,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019652 |
| At date | 2024-12-31 | 4,346,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019652 |
| At date | 2023-12-31 | 4,060,000 | USD | 2025-02-27 | 10-K · 0001410578-25-000216 |
| At date | 2022-12-31 | 3,747,000 | USD | 2024-02-26 | 10-K · 0001410578-24-000076 |
| At date | 2021-12-31 | 3,551,000 | USD | 2023-02-28 | 10-K · 0001104659-23-026701 |
| At date | 2020-12-31 | 3,815,000 | USD | 2022-02-28 | 10-K · 0001104659-22-028070 |
| At date | 2019-12-31 | 4,031,000 | USD | 2021-03-29 | 10-K · 0001104659-21-043161 |
| At date | 2018-12-31 | 6,111,000 | USD | 2020-03-26 | 10-K · 0001047469-20-001809 |
| At date | 2017-12-31 | 10,372,000 | USD | 2019-03-07 | 10-K · 0001047469-19-000992 |
| At date | 2016-12-31 | 13,192,000 | USD | 2018-03-07 | 10-K · 0001047469-18-001363 |
| At date | 2015-12-31 | 11,461,000 | USD | 2017-03-14 | 10-K · 0001047469-17-001564 |
| At date | 2014-12-31 | 10,535,000 | USD | 2016-02-25 | 10-K/A · 0001047469-16-010396 |
| At date | 2013-12-31 | 9,973,000 | USD | 2015-02-24 | 10-K · 0001047469-15-001081 |
| At date | 2012-12-31 | 7,205,000 | USD | 2014-03-03 | 10-K · 0001047469-14-001653 |
| At date | 2011-12-31 | 9,093,000 | USD | 2013-03-08 | 10-K · 0001047469-13-002403 |
| At date | 2010-12-31 | 10,832,000 | USD | 2012-03-08 | 10-K · 0001047469-12-002276 |
Related financial histories
- Celldex Therapeutics, Inc.: total assets
- Celldex Therapeutics, Inc.: total liabilities
- Celldex Therapeutics, Inc.: stockholders equity
- Celldex Therapeutics, Inc.: cash and cash equivalents
- Celldex Therapeutics, Inc.: net income or loss
- Celldex Therapeutics, Inc.: operating cash flow
- Celldex Therapeutics, Inc.: capital expenditure payments
- Celldex Therapeutics, Inc.: revenue
- Celldex Therapeutics, Inc.: contract revenue excluding tax
- Celldex Therapeutics, Inc.: financing cash flow
- Celldex Therapeutics, Inc.: investing cash flow
- Celldex Therapeutics, Inc.: retained earnings or deficit
- Celldex Therapeutics, Inc.: basic weighted-average shares
- Celldex Therapeutics, Inc.: diluted weighted-average shares
- Celldex Therapeutics, Inc.: basic earnings per share
- Celldex Therapeutics, Inc.: diluted earnings per share
- Celldex Therapeutics, Inc.: income tax expense or benefit
- Celldex Therapeutics, Inc.: share-based compensation expense
- Celldex Therapeutics, Inc.: operating income or loss
- Celldex Therapeutics, Inc.: current assets
- Celldex Therapeutics, Inc.: interest expense
- Celldex Therapeutics, Inc.: current liabilities
- Celldex Therapeutics, Inc.: current accounts payable
- Celldex Therapeutics, Inc.: goodwill carrying amount
- Celldex Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Celldex Therapeutics, Inc. / CIK 0000744218
- Captured
- 2026-09-19T15:01:25.275Z
- SEC response SHA-256
a253f724b1319f3eeec0fb678b43576159c8fa993fc97e4268adfafa9963e2f2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000744218.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))